Suprasorb® CNPendo Used for Negative Pressure Therapy in the Oesophagus and Rectum to Support Defect and Wound Healing

Esophagus Injury Clinical Trial

— Velox  

Official title:

Non-interventional, Observational, Prospective, Multicentre Study in a Routine Clinical Care Setting Using a Marketed Medical Device in Line With the Corresponding IFU in the Intended Patient Population

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05476263
• Other study ID #: 2022-03
• Status: Not yet recruiting
• Start date: June 2024
• Est. completion date: September 2027

Study information

• Verified date: June 2024
• Source: Lohmann & Rauscher
• Contact: Daria Trofimenko, MD
• Phone: +49 (0)2631- 99 6385
• Email: Daria.Trofimenko[@]de.LRmed.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

A Post-Market Clinical Follow-up (PMCF) study designed as non-interventional, observational, prospective, multicentre study in a routine clinical care setting using a marketed medical device in line with the corresponding Instruction for Use (IFU) in the intended patient population.

Patients will be diagnosed and evaluated for eligibility in routine clinical care by expert centres in the indication of interest. They will be consecutively enrolled into the study provided that all inclusion and exclusion criteria are met and written consent is given to use their clinical routine data according to data privacy regulations.

The study protocol does not define specific study procedures for patients enrolled. Therapies and procedures during the course of this study will be performed according to the decision of the treating physician based on current applicable medical guidelines and on local policy in clinical routine care.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 110
• Est. completion date: September 2027
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years of age

• Acute transmural defects, injuries and wounds in oesophagus or rectum, including perforations (iatrogenic or spontaneous) and anastomotic insufficiencies (Index defect)

• Indication of treatment with Suprasorb® CNPendo system according to IFU and medical guidelines

• Signed informed consent for usage of data

Exclusion Criteria:

• Pre-existing coagulation disorders with increased risk of bleeding

• Defects involving the bronchial system (bronchus/trachea/pulmo)

• Any foreseeable deviation from IFU of Suprasorb® CNP endo

• Known intolerance or allergy to one or more components of Suprasorb® CNPendo

Related Conditions & MeSH terms

• Esophagus Injury
• Rectal Lesion

Locations

Country	Name	City	State
Germany	Central Interdisciplinary Endoscopy, II. Medical Clinic Mannheim Medical University	Mannheim
Germany	Clinic for general, visceral and transplant surgery at the University of Munich	Munich

Sponsors (2)

Lead Sponsor	Collaborator
Lohmann & Rauscher	CRI-The Clinical Research Institute GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time period in days from index use of Suprasorb® CNPendo to release for oral food intake (in upper GI tract use) or release for stoma relocation (in lower GI tract use).	Time period in days from index use of Suprasorb® CNPendo to release for oral food intake (in upper GI tract use) or release for stoma relocation (in lower GI tract use).; In case of lower GI tract use and no stoma present, time period to release for oral food intake is the relevant endpoint.	3 months